## Gus A Baker

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5141681/publications.pdf

Version: 2024-02-01

		19608	20307
158	14,264	61	116
papers	citations	h-index	g-index
150	150	150	9244
159	159	159	8244
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet, The, 2007, 369, 1000-1015.	6.3	873
2	The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet, The, 2007, 369, 1016-1026.	6.3	850
3	Cognitive Function at 3 Years of Age after Fetal Exposure to Antiepileptic Drugs. New England Journal of Medicine, 2009, 360, 1597-1605.	13.9	754
4	Quality of Life of People with Epilepsy: A European Study. Epilepsia, 1997, 38, 353-362.	2.6	691
5	Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurology, The, 2013, 12, 244-252.	4.9	665
6	Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: A staged approach. Epilepsia, 2013, 54, 2005-2018.	2.6	601
7	The Clinical Course of Epilepsy and Its Psychosocial Correlates: Findings from a U.K. Community Study. Epilepsia, 1996, 37, 148-161.	2.6	565
8	The Stigma of Epilepsy: A European Perspective. Epilepsia, 2000, 41, 98-104.	2.6	299
9	Predictors of health-related quality of life and costs in adults with epilepsy: A systematic review. Epilepsia, 2011, 52, 2168-2180.	2.6	283
10	Patients' Experiences of Injury as a Result of Epilepsy. Epilepsia, 1997, 38, 439-444.	2.6	271
11	IQ at 6 years after in utero exposure to antiepileptic drugs. Neurology, 2015, 84, 382-390.	1.5	226
12	Breastfeeding in Children of Women Taking Antiepileptic Drugs. JAMA Pediatrics, 2014, 168, 729.	3.3	201
13	Factors influencing compliance with antiepileptic drug regimes. Seizure: the Journal of the British Epilepsy Association, 1997, 6, 87-93.	0.9	188
14	Public Knowledge, Private Grief: A Study of Public Attitudes to Epilepsy in the United Kingdom and Implications for Stigma. Epilepsia, 2004, 45, 1405-1415.	2.6	183
15	Uptake and Costs of Care for Epilepsy: Findings from a U.K. Regional Study. Epilepsia, 1998, 39, 776-786.	2.6	175
16	The initial development of a health-related quality of life model as an outcome measure in epilepsy. Epilepsy Research, 1993, 16, 65-81.	0.8	173
17	The development of a seizure severity scale as an outcome measure in epilepsy. Epilepsy Research, 1991, 8, 245-251.	0.8	171
18	Epilepsy, psychosocial and cognitive functioning. Epilepsy Research, 2009, 86, 1-14.	0.8	165

#	Article	IF	CITATIONS
19	Impact of epilepsy in adolescence: A UK controlled study. Epilepsy and Behavior, 2005, 6, 556-562.	0.9	159
20	Quality-of-life trajectories in epilepsy: A review of the literature. Epilepsy and Behavior, 2008, 12, 557-571.	0.9	156
21	Seizure frequency, patient-perceived seizure severity and the psychosocial consequences of intractable epilepsy. Epilepsy Research, 1991, 9, 231-241.	0.8	152
22	Measuring the impact of epilepsy: the development of a novel scale. Epilepsy Research, 1993, 16, 83-88.	0.8	148
23	Semantic memory is impaired in patients with unilateral anterior temporal lobe resection for temporal lobe epilepsy. Brain, 2012, 135, 242-258.	3.7	144
24	Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain, 2011, 134, 396-404.	3.7	140
25	Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years. Epilepsy and Behavior, 2013, 29, 308-315.	0.9	132
26	Indications and expectations for neuropsychological assessment in routine epilepsy care: Report of the ILAE Neuropsychology Task Force, Diagnostic Methods Commission, 2013–2017. Epilepsia, 2015, 56, 674-681.	2.6	130
27	Determinants of Quality of Life in People with Epilepsy. Neurologic Clinics, 2009, 27, 843-863.	0.8	128
28	Early cognitive development in children born to women with epilepsy: A prospective report. Epilepsia, 2010, 51, 2058-2065.	2.6	126
29	Relationship Between Seizure Frequency and Costs and Quality of Life of Outpatients with Partial Epilepsy in France, Germany, and the United Kingdom. Epilepsia, 1997, 38, 1221-1226.	2.6	123
30	The Use of the Canadian Occupational Performance Measure as an Outcome of a Pain Management Program. Canadian Journal of Occupational Therapy, 2001, 68, 16-22.	0.8	108
31	Cross-cultural differences in health-related quality of life of people with epilepsy: findings from a European study. Quality of Life Research, 1999, 8, 675-685.	1.5	105
32	Managing patient adherence and quality of life in epilepsy. Neuropsychiatric Disease and Treatment, 2007, 3, 117-131.	1.0	105
33	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1375-1386.	6.3	104
34	Quality of Life of People with Epilepsy in Iran, the Gulf, and Near East. Epilepsia, 2005, 46, 132-140.	2.6	103
35	The associations of psychopathology in epilepsy: a community study. Epilepsy Research, 1996, 25, 29-39.	0.8	102
36	Levels of epilepsy stigma in an incident population and associated factors. Epilepsy and Behavior, 2011, 21, 255-260.	0.9	100

#	Article	IF	CITATIONS
37	Quantitative MRI of the prefrontal cortex and executive function in patients with temporal lobe epilepsy. Epilepsy and Behavior, 2009, 15, 186-195.	0.9	99
38	Employers' Attitudes to Employment of People with Epilepsy: Still the Same Old Story?. Epilepsia, 2005, 46, 1978-1987.	2.6	98
39	Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology, 2016, 87, 1943-1953.	1.5	98
40	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1363-1374.	6.3	93
41	Antiepileptic drug use in women of childbearing age. Epilepsy and Behavior, 2009, 15, 339-343.	0.9	92
42	Does alexithymia differentiate between patients with nonepileptic seizures, patients with epilepsy, and nonpatient controls?. Epilepsy and Behavior, 2005, 7, 430-437.	0.9	91
43	The relationship between seizure frequency, seizure type and quality of life: Findings from three European countries. Epilepsy Research, 1998, 30, 231-240.	0.8	88
44	Cross-cultural Differences in Levels of Knowledge aboutâ€∫Epilepsy. Epilepsia, 2003, 44, 115-123.	2.6	88
45	Emotional dysregulation, alexithymia, and attachment in psychogenic nonepileptic seizures. Epilepsy and Behavior, 2013, 29, 178-183.	0.9	88
46	Epilepsy surgery: patient-perceived long-term costs and benefits. Epilepsy and Behavior, 2004, 5, 81-87.	0.9	84
47	Cognitive/behavioral teratogenetic effects of antiepileptic drugs. Epilepsy and Behavior, 2007, 11, 292-302.	0.9	84
48	Liverpool Seizure Severity Scale revisited. Seizure: the Journal of the British Epilepsy Association, 1998, 7, 201-205.	0.9	82
49	Characteristics associated with quality of life among people with drug-resistant epilepsy. Journal of Neurology, 2017, 264, 1174-1184.	1.8	77
50	Current Issues in the Management of Epilepsy: The Impact of Frequent Seizures on Cost of Illness, Quality of Life, and Mortality. Epilepsia, 1997, 38, S1-8.	2.6	76
51	Fetal antiepileptic drug exposure: Motor, adaptive, and emotional/behavioral functioning at age 3years. Epilepsy and Behavior, 2011, 22, 240-246.	0.9	76
52	Patient-Based Assessments of Quality of Life in Newly Diagnosed Epilepsy Patients: Validation of the NEWQOL. Epilepsia, 2000, 41, 1119-1128.	2.6	75
53	Developing a measure to assess attitudes toward epilepsy in the US population. Epilepsy and Behavior, 2004, 5, 965-975.	0.9	75
54	Perceived impact of epilepsy in teenagers and young adults: An international survey. Epilepsy and Behavior, 2008, 12, 395-401.	0.9	75

#	Article	IF	Citations
55	Seizure Severity and the Quality of Life. Epilepsia, 1993, 34, S31-5.	2.6	74
56	Long-term accelerated forgetting of verbal and non-verbal information in temporal lobe epilepsy. Cortex, 2012, 48, 317-332.	1.1	72
57	People with epilepsy: what do they know and understand, and how does this contribute to their perceived level of stigma?. Epilepsy and Behavior, 2002, 3, 26-32.	0.9	70
58	Stress and avoidance in Pseudoseizures: testing the assumptions. Epilepsy Research, 1999, 34, 241-249.	0.8	66
59	Reliability, validity and responsiveness of a revised scoring system for the Liverpool Seizure Severity Scale. Epilepsy Research, 2001, 44, 53-63.	0.8	64
60	Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy and Behavior, 2003, 4, 710-716.	0.9	64
61	Childhood Family Dysfunction and Associated Abuse in Patients With Nonepileptic Seizures. Psychosomatic Medicine, 2003, 65, 695-700.	1.3	64
62	Newly diagnosed epilepsy: Cognitive outcome after 12â€∫ months. Epilepsia, 2011, 52, 1084-1091.	2.6	64
63	Development of a new seizure severity questionnaire: initial reliability and validity testing. Epilepsy Research, 2002, 48, 187-197.	0.8	62
64	Non-epileptic attack disorder: a psychological perspective. Seizure: the Journal of the British Epilepsy Association, 1997, 6, 429-434.	0.9	60
65	Assessment of Quality of Life in People with Epilepsy: Some Practical Implications. Epilepsia, 2001, 42, 66-69.	2.6	60
66	Selfâ€reported and parentâ€reported quality of life of children and adolescents with newâ€onset epilepsy. Epilepsia, 2011, 52, 1489-1498.	2.6	59
67	Fetal antiepileptic drug exposure and cognitive outcomes. Seizure: the Journal of the British Epilepsy Association, 2017, 44, 225-231.	0.9	54
68	Neuropsychological Outcomes in Randomized Controlled Trials of Antiepileptic Drugs: A Systematic Review of Methodology and Reporting Standards. Epilepsia, 1998, 39, 1088-1097.	2.6	53
69	Persistent seizures following left temporal lobe surgery are associated with posterior and bilateral structural and functional brain abnormalities. Epilepsy Research, 2007, 74, 131-139.	0.8	53
70	Factors predictive of resilience and vulnerability in new-onset epilepsy. Epilepsia, 2011, 52, 610-618.	2.6	52
71	The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy and Behavior, 2012, 24, 36-43.	0.9	52
72	The development, reliability and validity of a disease specific quality of life model for adults with growth hormone deficiency. Clinical Endocrinology, 1996, 44, 403-411.	1.2	51

#	Article	IF	Citations
73	The Neuropsychiatry and Neuropsychology Of Lipoid Proteinosis. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 86-92.	0.9	50
74	The neuropsychological and emotional consequences of living with intractable temporal lobe epilepsy: implications for clinical management. Seizure: the Journal of the British Epilepsy Association, 2002, 11, 224-230.	0.9	49
75	A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: Impact on seizures, severity, and quality of life. Epilepsy and Behavior, 2005, 7, 472-480.	0.9	49
76	The stigma of people with epilepsy is demonstrated at the internalized, interpersonal and institutional levels in a specific sociocultural context: Findings from an ethnographic study in rural China. Epilepsy and Behavior, 2012, 25, 282-288.	0.9	49
77	The development and validation of the Epilepsy and Learning Disabilities Quality of Life (ELDQOL) scale. Epilepsy and Behavior, 2007, 10, 38-43.	0.9	48
78	The base rate of effort test failure in patients with medically unexplained symptoms. Journal of Psychosomatic Research, 2008, 65, 319-325.	1,2	48
79	Quality-of-Life and Behavioral Outcome Measures in Randomized Controlled Trials of Antiepileptic Drugs: A Systematic Review of Methodology and Reporting Standards. Epilepsia, 2000, 41, 1357-1363.	2.6	47
80	Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero. Current Opinion in Neurology, 2009, 22, 162-166.	1.8	45
81	Modafinil for Parkinson's disease fatigue. Journal of Neurology, 2010, 257, 452-456.	1.8	45
82	Validation of the Wechsler Memory Scale-Revised in a Sample of People with Intractable Temporal Lobe Epilepsy. Epilepsia, 1996, 37, 1215-1220.	2.6	44
83	The SF-36 as a health status measure for epilepsy: a psychometric assessment. Quality of Life Research, 1999, 8, 351-364.	1.5	44
84	Recognition of emotion with temporal lobe epilepsy and asymmetrical amygdala damage. Epilepsy and Behavior, 2006, 9, 164-172.	0.9	44
85	Self reported adverse effects of mono and polytherapy for epilepsy. Seizure: the Journal of the British Epilepsy Association, 2012, 21, 610-613.	0.9	44
86	Newly diagnosed epilepsy: Cognitive outcome at 5 years. Epilepsy and Behavior, 2010, 18, 397-403.	0.9	42
87	Multiple impacts of epilepsy and contributing factors: Findings from an ethnographic study in Vietnam. Epilepsy and Behavior, 2009, 16, 512-520.	0.9	41
88	Lennox-Gastaut Syndrome (LGS): Development of conceptual models of health-related quality of life (HRQL) for caregivers and children. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 23-30.	0.9	41
89	The impact of counselling with a practical statistical model on patients' decision-making about treatment for epilepsy: Findings from a pilot study. Epilepsy Research, 1993, 16, 207-214.	0.8	40
90	A Review of Subjective Impact Measures for Use with Children and Adolescents with Epilepsy. Quality of Life Research, 2004, 13, 1435-1443.	1.5	40

#	Article	IF	CITATIONS
91	The A–B Neuropsychological Assessment Schedule (ABNAS): the further refinement of a patient-based scale of patient-perceived cognitive functioning. Epilepsy Research, 2001, 43, 227-237.	0.8	39
92	Self-reported anxiety and sleep problems in people with epilepsy and their association with quality of life. Epilepsy and Behavior, 2015, 43, 149-158.	0.9	38
93	Patients' Experiences of and Satisfaction with Care for Their Epilepsy. Epilepsia, 1996, 37, 841-849.	2.6	35
94	Indications and expectations for neuropsychological assessment in epilepsy surgery in children and adults: Executive summary of the report of the ⟨scp⟩ILAE⟨ scp⟩ Neuropsychology Task Force Diagnostic Methods Commission: 2017â€2021. Epilepsia, 2019, 60, 1794-1796.	2.6	35
95	Nondrug treatments for psychogenic nonepileptic seizures: What $\hat{a} \in \mathbb{N}$ the evidence? Epilepsy and Behavior, 2007, 11, 367-377.	0.9	32
96	Comparison of two types of dissociation in epileptic and nonepileptic seizures. Epilepsy and Behavior, 2008, 13, 333-336.	0.9	32
97	A comprehensive neuropsychological description of cognition in drug-refractory juvenile myoclonic epilepsy. Epilepsy and Behavior, 2014, 36, 124-129.	0.9	31
98	Cognitive and neurodevelopmental effects of antiepileptic drugs. Epilepsy and Behavior, 2011, 22, 9-16.	0.9	30
99	Relationship of clinical and quality of life trajectories following the onset of seizures: Findings from the UK MESS Study. Epilepsia, 2011, 52, 965-974.	2.6	30
100	Seizure frequency and patientâ€centered outcome assessment in epilepsy. Epilepsia, 2014, 55, 1205-1212.	2.6	30
101	Self-Management education for adults with poorly controlled epILEpsy (SMILE (UK)): a randomised controlled trial protocol. BMC Neurology, 2014, 14, 69.	0.8	30
102	Fetal antiepileptic drug exposure and learning and memory functioning at 6†years of age: The NEAD prospective observational study. Epilepsy and Behavior, 2019, 92, 154-164.	0.9	30
103	Learning disability and epilepsy. 2, A review of available outcome measures and position statement on development priorities. Seizure: the Journal of the British Epilepsy Association, 1997, 6, 337-350.	0.9	29
104	Relationship of child IQ to parental IQ and education in children with fetal antiepileptic drug exposure. Epilepsy and Behavior, 2011, 21, 147-152.	0.9	29
105	Executive functions and psychiatric symptoms in drug-refractory juvenile myoclonic epilepsy. Epilepsy and Behavior, 2014, 35, 72-77.	0.9	29
106	Patients' Understanding of and Adjustment to Epilepsy: Interim Findings from a European Survey. Epilepsia, 1999, 40, S26-S29.	2.6	28
107	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. British Journal of Clinical Pharmacology, 2015, 80, 1149-1159.	1.1	28
108	Qualityâ€ofâ€ife outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with newâ€onset epilepsy: Findings from the <scp>SANAD</scp> trial. Epilepsia, 2015, 56, 460-472.	2.6	28

#	Article	IF	Citations
109	Stress in midwifery: A comparison of midwives and nurses using the work environment scale. International Journal of Nursing Studies, 1994, 31, 13-22.	2.5	27
110	Cognitive and behavioural assessments in clinical trials: what type of measure?. Epilepsy Research, 2001, 45, 163-167.	0.8	27
111	The perceived health status of people with psychologically derived non-epileptic attack disorder and epilepsy: a comparative study. Seizure: the Journal of the British Epilepsy Association, 2004, 13, 71-75.	0.9	27
112	Stigma of people with epilepsy in China: Views of health professionals, teachers, employers, and community leaders. Epilepsy and Behavior, 2011, 21, 261-266.	0.9	27
113	A randomized controlled trial of a manual-based psychosocial group intervention for young people with epilepsy [PIE]. Epilepsy and Behavior, 2017, 72, 89-98.	0.9	26
114	The effectiveness of preconception counseling to reduce adverse pregnancy outcome in women with epilepsy: What's the evidence?. Epilepsy and Behavior, 2009, 14, 273-279.	0.9	25
115	Does the concept of resilience contribute to understanding good quality of life in the context of epilepsy?. Epilepsy and Behavior, 2016, 56, 153-164.	0.9	24
116	Cross-Country Measures for Monitoring Epilepsy Care. Epilepsia, 2007, 48, 990-1001.	2.6	23
117	Indications and expectations for neuropsychological assessment in epilepsy surgery in children and adults. Epileptic Disorders, 2019, 21, 221-234.	0.7	23
118	Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial. Health Technology Assessment, 2018, 22, 1-142.	1.3	23
119	Exploring loss and replacement of loss for understanding the impacts of epilepsy onset: A qualitative investigation. Epilepsy and Behavior, 2014, 33, 59-68.	0.9	22
120	The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsyâ $\in$ "a Canadian study. Seizure: the Journal of the British Epilepsy Association, 2002, 11, 6-15.	0.9	21
121	Tools for assessing quality of life in epilepsy patients. Expert Review of Neurotherapeutics, 2013, 13, 1355-1369.	1.4	20
122	The effectiveness of a group selfâ€management education course for adults with poorly controlled epilepsy, SMILE (UK): A randomized controlled trial. Epilepsia, 2018, 59, 1048-1061.	2.6	20
123	Patientâ€Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs. Clinical Pharmacology and Therapeutics, 2019, 105, 672-683.	2.3	20
124	Psychometric properties and factor structure of the wechsler memory scale-revised in a sample of persons with intractable epilepsy. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 897-905.	0.8	19
125	NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy. Epilepsy and Behavior, 2016, 54, 117-127.	0.9	19
126	Concordance between the Wada test and neuroimaging lateralization: Influence of imaging modality (fMRI and MEG) and patient experience. Epilepsy and Behavior, 2018, 78, 155-160.	0.9	18

#	Article	IF	Citations
127	Intellectual functioning in clinically confirmed fetal valproate syndrome. Neurotoxicology and Teratology, 2019, 71, 16-21.	1.2	18
128	The base rate of Wada test failure. Epilepsy and Behavior, 2008, 13, 630-633.	0.9	17
129	The Work Environment Scale: a comparison of British and North American nurses. Journal of Advanced Nursing, 1992, 17, 692-698.	1.5	16
130	Validation of the Wechsler Memory Scale-III in a population of people with intractable temporal lobe epilepsy. Epilepsy Research, 2003, 53, 201-206.	0.8	16
131	Self-management education for adults with poorly controlled epilepsy (SMILE (UK)): statistical, economic and qualitative analysis plan for a randomised controlled trial. Trials, 2015, 16, 269.	0.7	16
132	Simulating a memory impairment: Can amnesics implicitly outperform simulators?. British Journal of Clinical Psychology, 1998, 37, 31-48.	1.7	15
133	Predicting the psychosocial outcome of epilepsy surgery: A longitudinal perspective on the †burden of normality'. Epilepsy and Behavior, 2016, 60, 149-152.	0.9	14
134	A voxelâ€based asymmetry study of the relationship between hemispheric asymmetry and language dominance in Wada tested patients. Human Brain Mapping, 2018, 39, 3032-3045.	1.9	14
135	Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. Epilepsy and Behavior, 2014, 36, 12-17.	0.9	13
136	The reliability and validity of the Revised Liverpool Impact of Epilepsy Scale for use in people with new-onset epilepsy. Epilepsy and Behavior, 2013, 26, 175-181.	0.9	12
137	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Health Technology Assessment, 2021, 25, 1-134.	1.3	11
138	Clinical Neuropsychology as a Specialist Profession in European Health Care: Developing a Benchmark for Training Standards and Competencies Using the Europsy Model?. Frontiers in Psychology, 2020, 11, 559134.	1.1	9
139	Exploring the prevalence and profile of epilepsy across Europe using a standard retrospective chart review: Challenges and opportunities. Epilepsia, 2021, 62, 2651-2666.	2.6	9
140	Non-epileptic attack disorders in children and adolescents: a single case study. Seizure: the Journal of the British Epilepsy Association, 1995, 4, 307-309.	0.9	8
141	Health-related quality of life after transient ischemic attack and minor stroke: Is medical or surgical treatment influential?. Journal of Stroke and Cerebrovascular Diseases, 1998, 7, 70-75.	0.7	8
142	What really matters? A mixed methods study of treatment preferences and priorities among people with epilepsy in the UK. Epilepsy and Behavior, 2019, 95, 181-191.	0.9	8
143	Improved Quality of Life as an Outcome of Antiepileptic Drug Therapy. CNS Drugs, 1995, 3, 323-327.	2.7	7
144	Towards a comprehensive neuropsychological service in the united kingdom for adult patients being considered for epilepsy surgery. Seizure: the Journal of the British Epilepsy Association, 1994, 3, 25-28.	0.9	6

#	Article	IF	Citations
145	Health-related quality of life of adults with epilepsy. Epilepsy and Behavior, 2002, 3, 560-561.	0.9	6
146	Investigating imaging network markers of cognitive dysfunction and pharmacoresistance in newly diagnosed epilepsy: a protocol for an observational cohort study in the UK. BMJ Open, 2019, 9, e034347.	0.8	6
147	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). BMJ Open, 2020, 10, e040635.	0.8	6
148	Functional cognitive disorder: dementia's blind spot. Brain, 2021, 144, e37-e37.	3.7	5
149	Language ability and hippocampal integrity. Neurolmage, 2001, 13, 549.	2.1	2
150	Uses and abuses of the neuropsychological assessment in the presurgical evaluation of epilepsy surgery candidates. Epilepsy and Behavior Reports, 2022, 18, 100507.	0.5	2
151	Measuring quality of life in adults with growth hormone deficiency. Clinical Endocrinology, 1996, 45, 507-508.	1.2	1
152	Introduction: Tracing the recent history of the †falling sickness'. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 615-616.	0.9	1
153	Comments on De Boer JE et al. The global burden and stigma of epilepsy. Epilepsy & Behavior 2008;12:540–546. Epilepsy and Behavior, 2014, 40, 20-21.	0.9	1
154	The Hillsborough football stadium disaster: a single case study. Irish Journal of Psychological Medicine, 1992, 9, 57-59.	0.7	0
155	A review of neuropsychological services in the United Kingdom for patients being considered for epilepsy surgery. Seizure: the Journal of the British Epilepsy Association, 2002, 11, 217-223.	0.9	0
156	Conclusions. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 690-691.	0.9	0
157	In response to comments on Parietal seizures mimicking psychogenic nonepileptic seizures. Epilepsia, 2014, 55, 197-198.	2.6	0
158	Birthday congratulations from the UK. Epilepsy and Behavior, 2014, 40, 68.	0.9	0